fbpx
Home Tags Eric Schadt

Tag: Eric Schadt

Stamford’s Sema4 going public

The new entity will begin trading its shares of common stock and warrants on the Nasdaq Global Select Market under the ticker symbols "SMFR" and “SMFRW.”

Stamford’s Sema4 partners with AdventHealth to optimize patient care and outcomes

The companies initially will focus on accelerating research in AdventHealth’s Orlando-area network.

Wall Street and health care intersect for pair of Fairfield County...

Sema4 and Signify Health are raking in big bucks: The former through a merger with an eye toward going public, and the latter via its own IPO.

Stamford’s Sema4 being acquired in deal valued at $2B; Will go...

“The additional resources will allow us to greatly accelerate our business plans organically and inorganically, developing and bringing in more cutting-edge precision model solutions across multiple disease areas,” said Sema4 Founder and CEO Eric Schadt.

Sema4 opens 70,000-square-foot clinical lab in Stamford

Genomics-testing company Sema4 this morning opened its second clinical laboratory in Connecticut. The newly built 70,000-square-foot facility in Stamford – first announced in July 2019 –...

COVID-19 LATEST: Fairfield County passes 100 deaths; More testing coming online

Fairfield County's coronavirus-related death toll has reached 101, Gov. Ned Lamont announced today, though he said he was trying to draw some solace from the fact that an anticipated major spike in cases has, so far, not arrived.

Joel Sendek joins Sema4 as CFO

Sendek previously held CFO roles at Spero Therapeutics and Forward Pharma.

Sema4 increases commitment to Stamford, relocates lab from NYC

The health information technology company will receive a $6 million loan from the state that will be used for the purchase of machinery and equipment, capital improvements, and the creation of 408 jobs.

Stamford the hub for Fairfield County’s biotech sector

The Connecticut Business and Industry Association’s Connecticut Bioscience Growth Council is lobbying for legislation that's more friendly to venture capitalists.